Background: Inhibition of programmed death-ligand one (PD-L1) with atezolizumab can induce 28 durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete 29 remissions in patients with chemotherapy refractory disease. Although mutation load and PD-L1 30 immune cell (IC) staining have been associated with response, they lack sufficient sensitivity 31 and specificity for clinical use. Thus, there is a need to evaluate the peripheral blood immune 32 environment and to conduct detailed analyses of mutation load, predicted neoantigens and 33 immune cellular infiltration in tumors to enhance our understanding of the biologic underpinnings 34 of response and resistance. 35 36 Methods and Findings: We performed whole exome sequencing (WES), RNA sequencing 37 (RNA-seq), and T cell receptor sequencing (TCR-seq) of pre-treatment tumor samples as well 38 as TCR sequencing of matched, serially collected peripheral blood pre-and post-treatment with 39 atezolizumab. These parameters were assessed for correlation with DCB (defined as 40 progression free survival (PFS) > 6 months) and overall survival (OS), both alone and in the 41 context of clinical and intratumoral parameters known to be predictive of survival in this disease 42 state. 43 44 Patients with DCB displayed a higher proportion of tumor infiltrating T lymphocytes (TIL) (n=24, 45
Patients with DCB also demonstrated more substantial expansion of tumor-associated TCR 48 clones in the peripheral blood 3 weeks after starting treatment (n=22, Mann-Whitney p=0.022). 49
The combination of high pre-treatment peripheral blood TCR clonality with elevated PD-L1 IC Introduction 64 Atezolizumab has demonstrated responses in 15-25% of patients with advanced urothelial 65 carcinoma and improved survival compared to historical expectations (1, 2) . Similar to predictive 66 factor analyses in melanoma, colon cancer and non-small cell lung cancer studies with other 67 checkpoint blockade agents, Rosenberg and colleagues reported a statistically significant 68 association between mutation load and response to atezolizumab in urothelial cancer patients 69
(2). However, mutation load in the atezolizumab study was predicted based on an estimate 70 using a targeted panel and not with WES. Similar to findings from prior studies, the association 71 between this predicted mutation load and outcomes in patients with urothelial cancer was not 72 dichotomous; there were tumors from patients with elevated mutation load that did not respond 73 to therapy, and vice versa. Additionally, positive PD-L1 staining of infiltrating immune cells by 74 immunohistochemistry was associated with, but poorly predicted, response. A statistical model 75 suggested that both PD-L1 staining and mutation load impacted the likelihood of response. 76 However, the authors did not recommend its clinical use. 77
Collectively, studies to date imply that a combination of immune parameters are 78 necessary to gain further precision in determining the likelihood of benefit from these 79 immunotherapies and that a single biologic marker will be insufficient. There have been few 80 attempts to integrate molecular and immunologic data from patients treated with checkpoint 81 blockade and their tumors. Consequently we performed whole exome (WES), RNA, and T cell 82 receptor (TCR) sequencing of tumor samples from patients treated with atezolizumab as well as 83 TCR sequencing of matched, serially collected peripheral blood. 84
In this cohort of patients, we illustrate the importance of host immune factors, including 85 intratumoral and peripheral T cell receptor clonality, infiltration and expansion, to clinical 86 outcomes. We did not find a significant association between mutation or expressed neoantigen 87 load and progression free survival or DCB (defined as progression free survival (PFS) > 6 88 months). However, we did demonstrate a time-dependent relationship between mutation load 89 and outcome, implyling that patients who experienced rapid progression displayed systemic 90 indicators of immune deficiency despite elevated mutation load in the tumors. Calculation of the 91 hazard ratios for each measured biomarker and clinical factor underscores the concept that a 92 complex interaction of both host and tumor variables determines whether a patient will 93 experience clinical benefit from anti-PD-L1 therapy. All patients had locally advanced or metastatic urothelial carcinoma and were treated at 98 Memorial Sloan Kettering Cancer Center (n=29) on protocol NCT02108652 (2). All patients 99 initiated therapy in 2014 and were treated with atezolizumab 1200 mg IV every 3 weeks, and 100 had consented to Institutional Review Board-approved protocols permitting tissue and blood 101 collection and sequencing. Patient tumor samples were assessed prospectively and centrally 102 (by HistoGeneX, Brussels, Belgium) for PD-L1 expression by immunohistochemistry with the 103 SP142 assay (Ventana, AZ, USA) (1) . The PD-L1 tumor-infiltrating immune cell (IC) status was 104 defined by the percentage of PD-L1-positive immune cells in the tumor microenvironment: IC0 105 (<1%), IC1 (≥1% but <5%), and IC2/3 (≥5%) as defined in the original study. Smoking status 106 was evaluated using previously completed self-reported smoking questionnaires or review of 107 medical records. 108
109
Tumor and blood samples 110
All tumor tissue used for sequencing was obtained prior to dosing with atezolizumab. Tumor 111 samples used for whole exome sequencing were all formalin-fixed paraffin embedded (FFPE). 112
The presence of tumor tissue in the sequenced samples was confirmed by examination of a 113 representative hematoxylin and eosin-stained slide by a genitourinary pathologist (H.A.). 114
Peripheral blood mononuclear cells (PBMCs) were isolated and stored as previously described 115
(3). PBMC were collected pre-treatment and during treatment. Tumor responses to atezolizumab were evaluated by CT scan every 9 weeks for the first 12 119 months following day 1 of cycle 1. After 12 months, tumor assessments were performed every 120 12 weeks. The response evaluation criteria in solid tumors (RECIST) version 1.1 was used to 121 define objective clinical responses by the institutional radiologist. 122 123 DNA extraction and high-throughput TCRβ Sequencing 124
Genomic DNA was purified from total PBMCs and tumor samples using the Qiagen DNeasy 125
Blood extraction kit. The TCR CDR3 regions were amplified and sequenced using immunoSEQ 126 (Adaptive Biotechnologies, Seattle, WA) as previously described (4). In brief, bias-controlled V 127 and J gene primers were used to amplify rearranged V(D)J segments for high-throughput 128 sequencing at ~20X coverage. After correcting sequencing errors via a clustering algorithm, 129 CDR3 segments were annotated according to the International ImMunoGeneTics Collaboration 130 (5) to identify the V, D, and J genes that contributed to each rearrangement. A mixture of 131 synthetic TCR analogs in each PCR was used to estimate the absolute template abundance 132 (i.e., the number of cells bearing each unique TCR sequence) from sequencing data, as 133 previously described (6). The estimated TIL content was calculated as previously described (6-134 8). To determine TIL content in FFPE samples as a T cell fraction, we amplified several 135 housekeeping genes and quantitated their template counts to determine the amount of DNA 136 usable for TCRB sequencing. ImmunoSEQ then amplifies and sequences the molecules with 137 rearranged TCRb chains. Because the immunoSEQ assay aligns sequences to the the IMGT 138 database, sequences are annotated as complete VDJ rearrangements or non-productive 139 rearrangements (a stop codon or out of frame CDR3 region was generated during VDJ 140 recombination in one of the alleles; all downstream analysis in this work proceeded with 141 complete, productive sequences. To estimate the number of starting templates that were in the 7 sample, the number of sequence reads for each TCRB sequences is measured. Synthetic 143 control templates were also spiked into each sample, thereby enabling quantitation of input 144 TCRB templates from the read counts. To determine the proportion of T cells in the FFPE 145 samples, we amplified several housekeeping genes and quantitated their template counts to 146 determine the amount of DNA usable for TCRB sequencing. For each sample, Shannon entropy 147 was also calculated on the clonal abundance of all productive TCR sequences in the data set. 148
Shannon entropy was normalized to the range by dividing Shannon entropy by the logarithm of 149 the number of unique productive TCR sequences in the data set. This normalized entropy value 150 was then inverted (12 normalized entropy) to produce the clonality metric. Those T cell clones 151 whose frequencies differed between samples from a given subject taken at different time points, 152 or between cell populations (e.g., between total PBMCs and tumor) were computationally 153 identified as previously described (9). The input data consisted of the absolute abundance for 154 each TCR clone in each sample. Fisher's exact test was used to compute a p-value for each 155 clone across the two samples, against the null hypothesis that the population abundance of the 156 clone is identical in the two samples. We corrected for multiple testing to control FDR using the origin, greater than half of whom had a reported prior smoking history (Table 1) . Patients had an 244 ECOG performance status of 0 or 1, and had 0 to 3 prior regimens of chemotherapy. Of this 245 group, 25 patients had sufficient tumor tissue for WES, 26 for RNA-seq and 24 for TCR-seq. 29 246 had a pre-treatment peripheral blood sample on which TCR-Seq could be performed; 24 had 247 one pre-treatment and at least one post-treatment peripheral blood collection. 248 249 The importance of T cells to the anti-tumor response has long been known (13); the relevance 255 of intratumoral and peripheral T cell receptor (TCR) clonality to the anti-tumor response is an 256 area of active study. A single previous study of melanoma patients treated with anti-PD-1 257 therapy demonstrated that patients whose tumors featured both high levels of tumor infiltrating T 258 lymphocytes (TIL) along with high TIL clonality were more likely to experience radiographic 259 response to therapy (8). A separate study examined the peripheral TCR repertoire in anti-CTLA-260 4-treated patients with prostate cancer or melanoma, and found that clonotype stability was 261 associated with response (14). To our knowledge, no prior study has reported both intratumoral 262 and peripheral TCR clonality in a single population treated with checkpoint blockade therapy. 263
We performed TCR sequencing of tumors and peripheral blood mononuclear cells 264 In our patient group, we first asked whether there was an association between outcome 273 and either tumor TCR clonality or TIL proportion, or with TCR clonality in the peripheral blood. 274
Consistent with the data from Tumeh and colleagues (8), tumors from patients who experienced 275 a DCB exhibited a higher TIL proportion and higher TCR clonality than those patients who 276 experienced progressive disease ( Fig 1A, Supplementary Fig S1A) . Importantly, TIL proportion 277 alone was also associated with DCB, with a median of 0.21 (range 0.049-0.33) in tumors from 278 patients who had PFS greater than 6 months, versus 0.069 (range 0.0098-0.24) in tumors from 279 patients who did not (n=24, Mann-Whitney p=0.047, Fig 1B) ; it remains unclear whether TIL 280 clonality adds to TIL proportion in its association with DCB in this study (TIL proportion and 281 clonality versus TIL proportion alone, n=24, log-likelihood p=0.100). We next examined pre-treatment peripheral blood clonality and its relationship to DCB. 308 T cell population is present, we hypothesized that T cell receptor clonality would be inversely 310 associated with response. Indeed, low pre-treatment peripheral TCR clonality associated with 311 improved PFS (n=29, log-rank p=0.048) and OS (n=29, log-rank p=0.011) ( Figs 1C, 1D, 1E) , 312
although not with DCB ( Fig 1F) . 313
Finally, we explored the relationship between intratumoral and peripheral TCR clonality. 314
Variations in individual T cell clones present in tumors can be tracked in the peripheral blood 315 during treatment (examples in Supplementary Fig S1B) . Expansion of tumor-associated TCRs 316 occurred in the peripheral blood in all patients ( Fig 1G) . However, a more pronounced 317 expansion of intratumoral TCR clones was observed in DCB patients at three weeks after 318 initiation of treatment (second dose of therapy) ( Fig 1H) that diminished by 6 weeks after 319 therapy initiation ( Supplementary Fig S1C) . Interestingly, all patients with low pre-treatment 320 peripheral TCR clonality and high TIL clonality survived greater than one year (Supplementary 321 Fig S1D) . variants were identified and annotated as silent, missense or nonsense mutations (Fig 2A) . 329
There was no significant association between median missense mutation load and DCB 330 (median mutations per megabase 3.24 (range 0.038-11.46) in patients with DCB compared to 331 0.45 (range 0.019-9.90) in those without DCB, n=25, Mann-Whitney p=0.22, Fig 2B) . There was also no significant association between missense mutation load and overall survival greater 333 than 12 months (n=25, Mann-Whitney p=0.37, Supplementary Fig S2A) . In a survival analysis 334 for time to disease progression or mortality, the estimated hazard ratio associated with increase 335 in missense SNV count per megabase was 0.92 (95% CI 0.78 -1.09). These results are not 336 surprising given that the present sample size (n=25) is underpowered to detect an effect of 337 magnitude similar to that observed by Rosenberg Supplementary Fig S2B) . Consistent with known importance of specific variant calling 356 pipelines to output (15,16), we found that different filtering techniques impacted the association 357 with DCB ( Supplementary Table S1 ). Missense mutation load, when counting only mutations 358 that were removed after post-processing (via Base Quality Score Recalibration (BQSR) and 359 depth/variant allele frequency (VAF) filtering), was predictive of response (n=25, Mann-Whitney 360 p=0.0078). 361
One hypothesis for explaining the association between mutation load and outcome to 362 treatment with checkpoint blockade is the generation of neoantigens, altered peptides presented 363 by the major histocompatibility complex that are capable of eliciting an anti-tumor T cell 364 response and are more common with increased mutation load. After performing in silico HLA 365 typing (Methods), we examined predicted neoantigens that are 8 to 11 amino acids in length 366 resulting from the nonsynonymous mutations of patients treated with atezolizumab. There was 367 no significant association between predicted neoantigens per megabase and either DCB or 12 368 month overall survival. Patients with DCB had a median 4.58 (range 0.037-39.48) predicted 369 neoantigens per megabase while patients without DCB had 1.35 (range 0.00-20.22) (n=25, 370 only on those expressed in RNA (Methods) also demonstrated no significant association 372 between expressed predicted neoantigens and clinical benefit with atezolizumab (n=25, Mann-373 Whitney p=0.29, Fig 2C and Supplementary Fig S2B) . Again, we acknowledge the limitations in 374 statistical power to detect associations due to the sample size of our study. 375 376 Impact of mutation load on response likelihood increases over time 377 Given that the mutation load and outcomes were weakly associated in the complete IMvigor210 378 dataset and not statistically significantly associated in this cohort, we embarked upon an 379 exploration of additional factors, including tumor microenvironmental and systemic measures, 380 which may modify the importance of this variable or independently impact outcomes. 381
To this end, we examined the time-varying impact of mutation load on PFS to see if 382 mutation load had a differential impact on early hazards in contrast to late hazards. We found 383 evidence of time-varying effects of somatic mutation load on progression-free survival in this 384 cohort (n=25, p=0.044 for association of scaled Schoenfeld residuals with log(time)). There was 385 little association of somatic mutation load with mortality or disease progression in the first 3 386 months (n=25, HR=0.91, 95% CI (0.75, 1.07); Fig 3A) . In contrast, there was a notable 387 association of somatic mutation load with clinical events occurring more than 3 months after 388 treatment (n=11, HR=0.69, 95% CI (0.38, 0.99)). When a similar analysis was performed for 389 time-varying association with OS, the evidence in support of time-varying effects was similar 390 (n=25, p=0.082, Fig 3B) . Among patients who survived longer than 3 months, the number of 391 somatic mutations per megabase was associated with a lower risk of mortality (n=11, HR=0.80, 392 95% CI (0.60, 1.00)) than during the first three months (n=25, HR=1.02, 95% CI (0.79, 1.22), Fig  393   3B ). There was, however, weak evidence in support of a threshold at 3 months after follow-up. 394
In a nonparametric analysis, we found that the reduction in risk associated with somatic 395 mutation load increased steadily over time (Figs 3C, 3D, 3E) . 396
Fig 3. Time dependent relationship between mutation load and treatment response. 398
(A) There was no significant association between somatic mutation load and PFS for events 399 occurring in the first 3 months (red box: HR=0.91, 95% CI (0.75, 1.07)), as compared to those 400 more than 3 months following therapy (blue box: HR=0.69, 95% CI (0.38, 0.99)). (B) There was 401 no significant association between somatic mutation load and OS for events occurring in the first 402 3 months (red box: HR=1.02, 95% CI (0.79, 1.22)), as compared to those more than 3 months 403 following therapy (blue box: HR=0.80, 95% CI (0.60, 1.00)). which no failure or censor events were observed. Note that these estimates are not independent from one another since the model utilizes a random-walk parameterization to allow the variance 423 in hazard over time to be modeled flexibly. 424 425 These data suggest that in patients with rapidly progressive disease, factors other than 426 mutation load likely determine their outcome. This observation is not surprising in that clinical 427 factor analysis of this disease state has identified a heterogeneous population of patients, with 5 428 clinical factors distinguishing those likely to experience a rapid and early death from those more 429 likely to survive longer (11). We hypothesized that such patients might simply be too clinically 430 and systemically unwell to mount the necessary immune response, despite some of them 431 harboring tumor biomarkers thought to confer a likelihood of DCB, including elevated mutation 432 load. When we examined the 5-factor score in this subset relative to the rest of the dataset, we 433 found that indeed patients who survived less than or equal to 3 months exhibited a significantly 434 higher 5-factor score (3.00 (range 2.00-4.00), in contrast to 1.50 (range 0.00-4.00) in patients 435 who survived longer than 3 months (n=26, Mann-Whitney p=0.018, Supplementary Fig S3A) . 436
Patients surviving less than 3 months were much more likely to have liver metastases: 100% in 437 patients surviving less than or equal to 3 months and 22% in patients surviving longer than 3 438 months (n=29, Fisher's Exact p=0.00097, Supplementary Fig S3B) . There were no significant 439 differences in these patients with respect to BCG exposure (n=29, Fisher's Exact p=0.20), 440 missense SNV load (n=25, Mann-Whitney p=0.26) and pre-treatment peripheral TCR clonality 441 (n=29, Mann-Whitney p=0.12). These data suggest that there is a subset of nearly end-stage 442 patients with cancer in whom clinical variables may negate immunological response despite the 443 presence of one or more favorable tumor-associated biomarkers. The inclusion of these clinical 444 variables is warranted in future studies. 445
446
Examination of the tumor microenvironment shows evidence for adaptive 447 immunity and suppression in responding tumors 448 Several studies have suggested that an "inflamed" tumor microenvironment, tumor or immune 449 cell PD-L1 expression increase the likelihood of response to checkpoint blockade. As seen in 450 the published IMVigor 210 cohort, PD-L1 IC expression was significantly associated with DCB in 451 this subset (n=29, Spearman rho=0.48 p=0.0083, Supplementary Fig S4A) . We quantified 452 immune infiltration from RNA-seq using ESTIMATE (17). The immune score, while associated 453 with the TIL proportion estimated through TCR Seq ( Supplementary Fig S4B) , was estimated to 454 be 764.37 (range -1195.08-1509.65) in patients with DCB and 263.49 (range -1100.78-1734.28) 455 in patients without DCB but was not significantly different (n=26, Mann-Whitney p=0.33, 456 Supplementary Fig S4C) . When we performed gene set enrichment analysis (GSEA) using the 457 Hallmark Geneset (18), we did not observe any differentially expressed gene sets between 458 tumors from patients with DCB versus no DCB. Furthermore, RNA expression of PD-L1 did not 459 correlate with reported immune cell PD-L1 staining level (n=26, Spearman rho=0.045 p=0.83, 460 Supplementary Fig S4D) . We did not observe a difference in tumor MHC class I expression 461 according to DCB ( Supplementary Fig S4E, HLA-A: n=26, Mann-Whitney p=0.26, HLA-B: n=26, 462
Mann-Whitney p=0.36, HLA-C: n=26, Mann-Whitney p=0.24). 463
Given that such agnostic approaches did not reveal a clear association between tumor 464 microenvironment factors and response, we pursued a hypothesis-driven approach examining 465 the genes that show upregulation at the cell surface during T cell exhaustion. When categorized 466 by DCB, there was no significant difference in expression of such genes, including CTLA-4, 467
TIGIT, HAVCR2 (TIM-3) or LAG-3 (19). When grouped by PD-L1 staining, we found low 468 expression of all markers in the PD-L1 low group (IC0), as expected. However, in the PD-L1 469 high group (IC2), HAVCR exhibited significantly higher expression in tumors from patients who experienced DCB than in those who did not ( Supplementary Fig S4F) . Interestingly, of the three 471 IC2 tumors, two had missense SNV loads significantly below the median (17 and 57); the third 472 had 412 SNVs. Additionally, although Rosenberg and colleagues (2) found that among the four 473 TCGA subtypes of RNA expression, luminal cluster II showed a significantly higher response 474 rate, no significant association was found here between the four clusters and DCB (n=20, 475
Fisher's Exact p=0.36) ( Supplementary Fig S4G) , nor between the luminal/basal sub- When examined in conjunction with mutation load, the greater the expression of PD-L1, 483 the more negative the association of mutation load with hazard (i.e. higher mutation load was 484 associated with longer survival). Among patients with tumors showing little-to-no expression of 485 PD-L1 (IC0 rated), each unit increase in missense SNV count per megabase was associated 486 with a negligible change in hazard (n=4, HR=1.43, 95% CI (0.75, 2.98)). Among patients with 487 tumors expressing PD-L1 at moderate or high levels (IC1 or IC2 staining), missense SNV count 488 per megabase was associated with lower risk for disease progression or mortality (among IC1: 489 n=11, HR=0.75, 95% CI (0.47, 1.14); among IC2: n=10, HR=0.73, 95% CI (0.48, 1.06)). 490
Although our limited sample size precludes making an assertion that mutation load is associated 491 with survival in any particular subgroup (e.g. when looking among IC1 and IC2 tumors alone); 492 our data do support the presence of an interaction among these variables (p=0.046 for interaction; Supplementary Fig S5A) . Given the plausibility of the finding that somatic mutation 494 load may correlate better with survival among patients with an inflamed tumor 495 microenvironment, the addition of somatic mutation load to PD-L1 IC staining warrants further 496 study. 497
We found a similar albeit weaker interaction effect when looking at association of 498 somatic mutation load (missense SNV count per megabase) and progression-free survival 499 according to the presence/absence of liver metastasis prior to treatment administration (p=0.14 500 for interaction). Among patients without liver metastasis, somatic mutation load was associated 501 with a lower risk for disease progression or mortality (n=16, HR=0.73, 95% CI (0.50, 1.02), 502 Supplementary Fig S5B) than patients with liver metastasis (n=9, HR=0.96, 95% CI (0.66, 1.37), 503 Supplementary Fig S5B) . 504
To our surprise, although both PD-L1 staining and mutation load were each associated 505 with response in the original study (2) these variables did not correlate with each other (Fig 4A) . 506 Furthermore, pre-treatment peripheral TCR clonality did not correlate with mutation load (Fig  507   4B ). The lack of association between these variables suggests that each might confer an 508 independent or semi-independent impact on the likelihood of response to therapy. TCR clonality 509 and infiltration did, however, correlate with PD-L1 IC score: those tumors with higher clonality or 510 higher infiltration also featured higher PD-L1 staining (p=0.02 and p=0.01, respectively, Figs In an analysis to see whether the association between pre-treatment peripheral TCR 529 clonality and progression-free survival varied by PD-L1 IC score, we found some evidence of an 530 interaction (p=0.015 for interaction; Fig 4E) . Among patients with low levels of PD-L1 531 expression, there was little association between pre-treatment peripheral TCR clonality and 532 progression-free survival (among IC0: n=4, HR=1.87, 95% CI (0.49, 4.86); among IC1: n=11, 533 HR=0.69, 95% CI (0.14, 1.85)). Among patients with high levels of PD-L1 expression, by 534 comparison, we observed almost complete separation of progression-free survival according to 535 pre-treatment peripheral TCR clonality (among IC2: n=10, HR=86.22, 95% CI (2.55, 491.65); 536 Fig 4E) . Similar results were seen in analyses with respect to OS, and in a logistic regression 537 analysis for DCB ( Supplementary Figs 5C, 5D, 5E ). 538
To resolve the hypothesis that those patients with low peripheral TCR clonality simply 539 were healthier, we examined the association between 5-factor score and pre-treatment peripheral TCR clonality and did not find such an association (n=26, Spearman rho=0.25 541 p=0.22, Supplementary Fig S5F) . 542
In a multivariate survival model for time to disease progression or mortality, which allows 543 the effect of each biomarker to vary according to intratumoral PD-L1 IC score, we find that the 544 correlation of each intratumoral, peripheral or clinical biomarker with disease progression or 545 mortality is relatively independent of the others (Fig 4F, Supplementary Fig S5G) . Perhaps with 546 the notable exception of the impact of liver metastatic status on time to progression or survival, 547 the correlation of each intratumoral or peripheral biomarker with outcome is strongest in the 548 group with the highest levels of immune cell PD-L1 expression ( Supplementary Table S2 ). 549 550 Discussion 551
The treatment of previously incurable metastatic solid tumors with checkpoint blockade agents 552 has led to dramatic success in a minority of patients, a finding that has generated substantial 553 excitement in the field, with associated correlative studies and drug development. Despite such 554 studies, a deeper understanding of the biology of response and resistance is often eclipsed by 555 the search for biomarkers. Of the multitude of studied biomarkers, to date, PD-L1 staining 556 (either tumor cell or immune cell) and mutation load have emerged as the most consistently 557 positive predictors of response to checkpoint blockade (10,20,21). However, in all studies the 558 exceptions are patients who benefit despite having tumors with low mutation load or who lack 559 high PD-L1 staining, which demonstrates the inadequacy of these biomarkers in excluding and 560 therefore denying a patient with limited or no treatment options access to potentially life-saving 561 therapy. 562
Here, we undertook the in-depth characterization of tumors and peripheral blood from 29 563 patients treated on IMvigor 210, a Phase II study in which 310 patients were treated with the 564 anti-PD-L1 agent atezolizumab. Although the overall study found significant associations 565 between mutation load as measured by the Foundation Medicine targeted sequencing panel 566 and radiographic response (2), there was no statistically significant association between 567 mutation load and durable clinical benefit or survival in the patient subset studied here, despite 568 the similarity of our study population to the parent study. This contrast may be due to a 569 combination of factors. First, though statistically significant, the association in the overall study 570 was not categorical: as in other studies of mutation load, this factor alone was not predictive of 571 response. Second, we have less power to detect this association in our smaller subset 572 compared with the larger studied cohort. Third, standardized definitions and calculations of 573 mutation load do not exist as yet; each published study has used differing methodologies 574
(2,10,20,21). Indeed, in this study, depending on the method used, the association between 575 mutation load and clinical outcomes varied from p<0.08 to p>0.4 (AUCs and p-values in 576 Supplementary Table S1 ). To illustrate the fickle nature of defining mutation load, counting only 577 the mutations excluded by BQSR, as opposed to only those remaining after BQSR, showed a 578 significant association with DCB. Together, these findings underscore the need for improved 579 and standardized mutation calling methods. The weak association of mutation load with DCB 580 and the lack of such standardization render this biomarker unfit for application to individual 581 patients at present. Furthermore, the time-dependent relationship between mutation load and 582 survival implies that a clinical and immunological state may exist in patients with advanced 583 cancer, such that patients with very rapidly progressing disease and expected death in <3 584 months do not respond despite the presence of positive biomarkers. 585
In an attempt to deepen our understanding of the biology of response and resistance, we 586 studied additional factors: immune factors, conveyed here as peripheral and intratumoral TCR clonality and TIL proportion; and systemic factors such as the 5-factor score and presence of 588 liver metastases. We found that even in this small dataset, TCR clonality below the median in 589 the peripheral blood prior to treatment, expansion of tumor-associated TCR in the periphery 3 590 weeks after initiating treatment, and higher TIL proportion all associated with clinical benefit. 591
These data suggest that TCR sequencing provided additional insights into response and 592 resistance beyond mutation load and PD-L1 staining. With respect to biomarker development, 593 our study implies that non-invasive metrics such as pre-treatment peripheral TCR clonality and 594 known prognostic features such as the presence of liver metastases may be worthy of further 595 study in urothelial cancer patients treated with PD-L1 blockade. 596
Finally, though limited in power by the small sample size, we attempted to integrate the 597 importance of the studied variables. This analysis demonstrated both hypothesized and 598 unexpected interactions. For example, while mutation burden seemed to associate with 599 outcome more significantly in PD-L1 IC1 and-2 tumors, high PD-L1 IC staining in the setting of 600 high peripheral TCR clonality was associated with a substantial hazard for poor outcome. Given 601 the significance of PD-L1 expression in mediating response to anti-PD-L1 therapy, the presence 602 of these interactions may argue in their favor as predictive rather than prognostic biomarkers. 603 Further analysis is required to elucidate the role of these biomarkers in mediating response to 604 checkpoint blockade. 605
In conclusion, we have demonstrated that to truly understand and ultimately circumvent 606 resistance to checkpoint blockade, we must pursue integrated studies of the somatic, immune 607 and systemic features of each treated patient. 608 609 610 611
